A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

✍ Scribed by Fanale, M. A.; Forero-Torres, A.; Rosenblatt, J. D.; Advani, R. H.; Franklin, A. R.; Kennedy, D. A.; Han, T. H.; Sievers, E. L.; Bartlett, N. L.

• Book ID: 124073549
• Publisher: American Association for Cancer Research
• Year: 2011
• Tongue: English
• Weight: 267 KB
• Volume: 18
• Category: Article
• ISSN: 1078-0432
• DOI: 10.1158/1078-0432.CCR-11-1425